Results: In total, 30 patients were analyzed (12 males, 18 females; median age 58.7 AE 11.17 with 33.3% of them were smokers and 13.3% of them were passive smokers). Tissue biopsies were obtained by pleural biopsy (63.3%), endobronchial biopsy (16.6%), and CT/Ultrasound guided biopsy (23.3%). All of them had EGFR mutations. 19 of them received TKI as the first line chemotherapy where else 6 of them received cisplatin based chemotherapy. Progression free survival (PFS) in the group received TKI were significantly longer (8.4 months) than group which received cisplatin based chemo (6.8 months).
Median target lesions, which treated by TKI's reduced from 48 mm (pretreatment) to 32.5 mm (post treatment. Non target lesions reduced to 15 mm (post treatment) from 23 mm (pretreatment). Many of them develop side effects of skin (46.7%).
Conclusion: There were clinical benefits for patients who received TKI as first line therapy in EGFR mutation patients. 
Methods:
We retrospectively examined non-small cell lung cancer (NSCLC) patients treated with Nivolumab or Pembrolizumab monotherapy. Using immunohistochemistry (IHC), the pre-anti-PD1 treatment tissue specimens were analyzed for a panel of factors involving immune microenvironments, including immune checkpoints (PD-L1, Galectin-9), immune cells (CD4+ T cells, CD8+ T cells, regulatory T cells, M1 and M2 macrophages), antigen presenting machines (MHC class I), and genetic alterations related to immune cells infiltrations (PTEN, beta-catenin). The results were correlated with the treatment response and survival of patients.
Results: Total 25 NSCLC cases were eligible for this study. We found tumor PD-L1, CD4+ T cells, and CD8+ T cells were associated with better objective response rate (ORR), disease control rate (DCR), and progression free survival (PFS). After incorporation of these biomarkers, an immune profile (PD-L1 >0% and either CD4+ T cell ≥ 10% or CD8+ T cell ≥10%) showed a better efficacy to predict ORR, DCR, and PFS. For ORR and DCR, the PPV of a positive immune profile was 54.5% and 90.1%, respectively; the NPV of a negative immune profile was 85.7% and 71.4%, respectively. Through multi-variate analysis, a positive immune profile and ECOG ≤ 1 were independently associated with longer PFS. patients still face problems with drug resistance and disease progression. So far, no patient has been found to small cell lung cancer (SCLC) transformation with an accompanying T790M mutation. This case was reported to explore the clinical manifestation, mechanism, and treatment of this situation mentioned above in lung adenocarcinoma treated with EGFR-TKIs to increase awareness.
We retrospectively analyzed the clinical manifestations and pathological data of one case who had undergone subsequent treatment with gefitinib and osimertinib and then received re-biopsy after disease progression. We searched PubMed databases with the keywords "transformation" "SCLC"and"T790M", and review the relevant literatures.
Results: Pleural puncture cytology and EBUS-TBNA was performed and the 45-year-old women was diagnosed to a EGFR-mutated lung adenocarcinoma. Positron emission tomography-computed tomography and magnetic resonance imaging showed advanced stage IV lung cancer. Then gefitinib was administered at a dose of 250 mg daily which maintained a clinical response for 5 months. After progression, blood NGS showed EGFR T790M mutation, and the patient received osimertinib 80 mg daily. After 5 months, she had a progression again and underwent a re-biopsy, while the results revealed SCLC transformation with an accompanying T790M mutation. She received chemotherapy plus osimer-
